Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
Progressive Multifocal Leukoencephalopathy: Epidemiology, Clinical Manifestations, and Diagnosis
www.UptoDate.com, May, Koralnik, I.J., 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Viral Infections of the Nervous System, Chronic Meningitis, and Prior Diseases, Progressive Multifocal Leukoencephalopathy
Adams & Victors Principles of Neurology, Chp 33, pg 767, Ropper, A.H.,et al, 2014
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Progressive Multifocal Leukoencephalopathy: Prognosis and treatment
UpToDate, June, Koralnik, I.J.,et al, 2011
Toxoplasmic Encephalitis IRIS in HIV-Infected Patients
JNNP 82:691-693, Martin-Blondel, G.,et al, 2011
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
NEJM 361:1067-1074, Chen,Y.,et al, 2009
JC Virus Granule Cell Neuronopathy: A Novel Clinical Syndrome Distinct from Progressive Multifocal Leukoencephalopathy
Ann Neurol 57:576-580, Koralnik,I.J.,et al, 2005
Involvement of JC Virus-Infected Mononuclear Cells From the Bone Marrow & Spleen in the Pathogen of PML
NEJM 318:301-305, 315-3171988., Houff,S.A.,et al, 1988